JAK1 inhibition with abrocitinib decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy

BACKGROUND: JAK1 is a signaling molecule downstream of cytokine receptors, including IL-4 receptor α. Abrocitinib is an oral JAK1 inhibitor; it is a safe and effective US Food and Drug Administration–approved treatment for adults with moderate-to-severe atopic dermatitis. OBJECTIVE: Our objective wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramsey, Nicole, Kazmi, Wajiha, Phelan, Matthew, Lozano-Ojalvo, Daniel, Berin, M. Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501208/
https://www.ncbi.nlm.nih.gov/pubmed/37711220
http://dx.doi.org/10.1016/j.jacig.2023.100103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501208/
https://www.ncbi.nlm.nih.gov/pubmed/37711220
http://dx.doi.org/10.1016/j.jacig.2023.100103

Ejemplares similares